This session will look at the opportunity for population-level risk reduction and increased commissioning focus on improving chronic respiratory disease care, namely asthma and COPD.

We will explore:

• burden, clinical inertia, and health inequalities that exist across asthma and COPD care
• the need to embed proactive risk reduction at the population level to prevent premature death associated with suboptimal care
• best practice examples of collaborative working initiatives that have demonstrated impact on patient outcomes and/or health inequality
• how to inspire action to adopt best practice and/or other innovations to improve care through commissioning.

This is a non-promotional session sponsored and organised by AstraZeneca.

AstraZeneca has provided a sponsorship grant towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the AstraZeneca sponsored symposia presentations.